Biomedicines · 10 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study in a mouse model of cardiac arrest found that early treatment with two synthetic antimicrobial peptides, Pep19-2.5 and Pep19-4LF, did not improve survival or long-term neurological outcomes compared to a saline control.
This study investigated the effects of two synthetic antimicrobial peptides (Pep19-2.5 and Pep19-4LF) on post-cardiac arrest syndrome in a mouse model. A total of 127 mice were included, randomized into peptide-treated and saline control groups, with survival and neurological outcomes assessed up to 28 days. The study measured plasma cytokines, neuronal injury markers, and brain tissue mRNA expression at 4 hours and 28 days. Results showed no significant benefit of either peptide on survival or neurological outcomes. While early plasma cytokine levels were similar across groups, the Pep19-4LF group showed a significant increase in the neuronal damage marker UCH-L1 at 4 hours. The authors conclude that early treatment with these peptides did not provide benefits in this model, suggesting that modulations in dose, timing, or administration might be needed.
